Medtronic plc, a leader in healthcare technology, will present its latest innovations in deep brain stimulation (DBS) at the International Congress of Parkinson’s Disease and Movement Disorders® (MDS Congress) in Philadelphia, Pennsylvania, from September 27 to October 1, 2024.

The company will hold an interactive session focused on its BrainSense™ technology, featuring patient Brandan Mehaffie, his neurologist Dr. Sol De Jesus, and neurosurgeon Dr. James McInerney, who will demonstrate how Brandan’s Percept™ PC neurostimulator with BrainSense™ aids in managing his Parkinson’s symptoms.

Medtronic’s Brain Modulation research experts will collaborate with Dr. Todd Herrington from Mass General Hospital to discuss insights from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial, which evaluates the safety and effectiveness of chronic adaptive DBS compared to continuous DBS in eligible patients.

Although the adaptive DBS technology is investigational and not yet FDA-approved for commercial use in the U.S. or available in Europe, it has been approved in Japan.

The Congress serves as a vital platform for scientific exchange, highlighting the importance of collaboration between academia and industry.

Medtronic has been committed to advancing the field of movement and neurological disorders for over 30 years and remains focused on progressing DBS therapy. Attendees can explore the future of DBS at the Medtronic Innovation Tech Suite, located behind exhibit booth #813.

The company's involvement at the MDS Congress will include a symposium titled “Real-world application of DBS BrainSense™ technology – The clinical journey” on September 30, along with various scientific abstracts and oral presentations covering topics like adaptive DBS programming, monopolar sensing efficiency, and patient-specific therapy management trends.

'This year’s MDS Congress is particularly significant for Medtronic, following recent advancements such as the FDA and CE Mark approvals of the Percept™ RC neurostimulator and the FDA approval of Asleep DBS for Parkinson’s disease and essential tremor, along with the publication of the ADAPT-PD clinical trial methods manuscript.

Since 1987, Medtronic has provided DBS therapy to over 185,000 patients with movement disorders and other conditions in more than 70 countries.





Source: medtronic.com

Report Abuse